Panacea Biotec Limited
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company's product portfolio includes prescription products in various therapeu… Read more
Panacea Biotec Limited (PANACEABIO) - Total Assets
Latest total assets as of September 2025: ₹12.54 Billion INR
Based on the latest financial reports, Panacea Biotec Limited (PANACEABIO) holds total assets worth ₹12.54 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Panacea Biotec Limited - Total Assets Trend (2005–2025)
This chart illustrates how Panacea Biotec Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Panacea Biotec Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Panacea Biotec Limited's total assets of ₹12.54 Billion consist of 42.3% current assets and 57.7% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹248.40 Million | 6.4% |
| Accounts Receivable | ₹751.30 Million | 5.8% |
| Inventory | ₹2.14 Billion | 16.6% |
| Property, Plant & Equipment | ₹6.37 Billion | 49.4% |
| Intangible Assets | ₹422.60 Million | 3.3% |
| Goodwill | ₹0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Panacea Biotec Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Panacea Biotec Limited's current assets represent 42.3% of total assets in 2025, a decrease from 69.9% in 2005.
- Cash Position: Cash and equivalents constituted 6.4% of total assets in 2025, up from 2.1% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 1.0% in 2005.
- Asset Diversification: The largest asset category is property, plant & equipment at 49.4% of total assets.
Panacea Biotec Limited Competitors by Total Assets
Key competitors of Panacea Biotec Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Panacea Biotec Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Panacea Biotec Limited generates 0.43x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Panacea Biotec Limited is currently not profitable relative to its asset base.
Panacea Biotec Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.54 | 1.54 | 1.00 |
| Quick Ratio | 0.98 | 1.03 | 0.66 |
| Cash Ratio | 0.05 | 0.28 | 0.00 |
| Working Capital | ₹1.88 Billion | ₹ 1.76 Billion | ₹ -22.40 Million |
Panacea Biotec Limited - Advanced Valuation Insights
This section examines the relationship between Panacea Biotec Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.65 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 4.0% |
| Total Assets | ₹12.90 Billion |
| Market Capitalization | $56.46 Million USD |
Valuation Analysis
Below Book Valuation: The market values Panacea Biotec Limited's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Panacea Biotec Limited's assets grew by 4.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Panacea Biotec Limited (2005–2025)
The table below shows the annual total assets of Panacea Biotec Limited from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹12.90 Billion | +3.96% |
| 2024-03-31 | ₹12.41 Billion | -2.40% |
| 2023-03-31 | ₹12.71 Billion | -27.73% |
| 2022-03-31 | ₹17.59 Billion | +49.37% |
| 2021-03-31 | ₹11.78 Billion | -15.30% |
| 2020-03-31 | ₹13.90 Billion | +1.07% |
| 2019-03-31 | ₹13.76 Billion | -14.43% |
| 2018-03-31 | ₹16.08 Billion | -10.70% |
| 2017-03-31 | ₹18.00 Billion | -2.93% |
| 2016-03-31 | ₹18.54 Billion | -3.94% |
| 2015-03-31 | ₹19.30 Billion | -0.66% |
| 2014-03-31 | ₹19.43 Billion | +5.65% |
| 2013-03-31 | ₹18.39 Billion | -8.29% |
| 2012-03-31 | ₹20.06 Billion | +15.15% |
| 2011-03-31 | ₹17.42 Billion | +3.32% |
| 2010-03-31 | ₹16.86 Billion | -1.50% |
| 2009-03-31 | ₹17.11 Billion | +31.67% |
| 2008-03-31 | ₹13.00 Billion | +37.76% |
| 2007-03-31 | ₹9.44 Billion | -6.62% |
| 2006-03-31 | ₹10.10 Billion | +114.51% |
| 2005-03-31 | ₹4.71 Billion | -- |